Susquehanna Fundamental Investments, LLC Aprea Therapeutics, Inc. Transaction History

Susquehanna Fundamental Investments, LLC

$4.33 Trillion
Q2 2024

Shares

5 transactions

Quarter	Operation	Price Per share	shares change	shares Held	SEC Form
Q3 2022 Nov 14, 2022	SELL	$0.71 - $13.6 $34,861 - $667,760	-49,100 Closed	0 $0
Q3 2021 Nov 15, 2021	BUY	$3.43 - $5.63 $168,413 - $276,433	49,100 New	49,100 $251,000
Q4 2020 Feb 16, 2021	SELL	$4.92 - $30.67 $120,540 - $751,415	-24,500 Closed	0 $0
Q3 2020 Nov 16, 2020	BUY	$21.66 - $38.86 $253,422 - $454,662	11,700 Added 91.41%	24,500 $589,000
Q2 2020 Aug 14, 2020	BUY	$25.47 - $39.69 $326,016 - $508,032	12,800 New	12,800 $496,000

Others Institutions Holding APRE

# of Institutions

2

Shares Held

899

Call Options Held

0

Put Options Held

0

Nbc Securities, Inc. Birmingham, AL

899
Shares

$3,227
0.0% of portfolio
Concourse Financial Group Securities, Inc. Birmingham, AL

0
Shares

$0
0.0% of portfolio

About Aprea Therapeutics, Inc.

Ticker APRE
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Description
Aprea Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on developing and commercializing novel cancer therapeutics that target DNA damage response pathways. Its lead product candidate is ATRN-119, an oral ATR inhibitor that is in phase 1/2a clinical trial to treat patients with advanced solid tumors. The company's products...

More about APRE

Track This Portfolio

Portfolio Update

Get notified when there are updates to the investment portfolio of Susquehanna Fundamental Investments, LLC, based on Form 13F filings with the SEC.

News

Stay updated on Susquehanna Fundamental Investments, LLC with notifications on news.